Hsv Vectors for the Destruction of Brain Tumors

Fraser, Nigel William

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Neurological Disorders and Stroke (NINDS)
• Type: Research Project (R01)
• Project #: 7R01NS037516-02
• Application #: 2901811
• Study Section: Special Emphasis Panel (ZRG1-NLS-1 (02))
• Program Officer: Jacobs, Tom P
• Project Start: 1998-05-01
• Project End: 2002-02-28
• Budget Start: 1998-11-01
• Budget End: 1999-02-28
• Support Year: 2
• Fiscal Year: 1998

Institution

• Name: University of Pennsylvania
• Department: Microbiology/Immun/Virology
• Type: Schools of Medicine
• DUNS #: 042250712
• City: Philadelphia
• State: PA
• Country: United States
• Zip Code: 19104

Publications

Thomas, Darby L; Fraser, Nigel W (2003) HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 8:543-51

Miller, Cathie G; Fraser, Nigel W (2003) Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 7:741-7

Miller, C G; Krummenacher, C; Eisenberg, R J et al. (2001) Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol Ther 3:160-8

Poptani, H; Duvvuri, U; Miller, C G et al. (2001) T1rho imaging of murine brain tumors at 4 T. Acad Radiol 8:42-7